Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 1, pp 153–163 | Cite as

mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance

  • Steffen Rausch
  • Daniel Schollenberger
  • Joerg Hennenlotter
  • Viktoria Stühler
  • Stephan Kruck
  • Arnulf Stenzl
  • Jens BedkeEmail author
Original Article – Cancer Research
  • 74 Downloads

Abstract

Purpose

Impaired regulation of the Akt/mammalian target of rapamycin (mTOR) pathway has been implicated in mechanisms related to neoplastic transformation in renal cell cancer (RCC) through enhancement of cell proliferation and survival and mTOR activation has been reported to occur due to phosphorylation of mTOR. To further determine the relevance of mTOR expression and activation and to analyze their putative role as a biomarker for systemic treatment in metastatic RCC, we investigated the expression of mTOR and phospho(p)-mTOR in primary RCC and metastases and correlated levels with pathological variables and clinical outcome.

Methods

Tissue microarrays (TMA) from paraffin-embedded tissue from 342 patients with primary clear cell renal cell carcinoma and 90 patients undergoing surgical resection for metastases were immunohistochemically stained for mTOR and p-mTOR and expression was quantified with immunoreactivity scores. Clinical patient characteristics and follow-up were recorded. Comparative evaluation of protein expression levels and association of expression with clinical variables and survival was performed.

Results

mTOR staining revealed differential expression in benign, primary and RCC metastasis (average staining score: 1.64, 0.78, and 1.44, respectively). Average staining of p-mTOR was 0.99 in benign kidney tissue, 0.73 in primary RCC and 1.14 in RCC metastasis tissue. Elevated mTOR expression in primary RCC tissue was associated with the presence of tumor necrosis, while a high level of p-mTOR was significantly correlated with advanced T-stage, high Fuhrman grade, the presence of tumor necrosis and sarcomatoid features. An elevated ratio of p-mTOR/mTOR was significantly correlated with advanced stage and sarcomatoid histology. mTOR expression was not predictive of overall survival (OS), while high p-mTOR levels were associated with impaired OS (p = 0.0046) and cancer-specific survival (p = 0.0067). In univariate analysis, advanced stage (HR 3.78), high Fuhrman grade (HR 4.0), the presence of tumor necrosis (HR 1.99), and sarcomatoid features (HR 5.12) were significant predictors of OS. Moreover, elevated levels of p-mTOR (HR 1.67) and an elevated ratio of p-mTOR/mTOR ratio (HR 1.73) were significantly predictive of OS. In the multivariate regression model only the presence of locally advanced tumors (HR 2.44) was of independent prognostic value for OS, while there was a trend for impaired OS for patients with a high p-mTOR (HR 1.27, p = 0.21).

Conclusions

Phosphorylated mTOR is differentially expressed in localized RCC and metastasis. Elevated phosphorylation of mTOR is associated with aggressive pathologic features and unfavorable outcome. Whether these findings portend to relevance for mTOR inhibition treatment for metastatic RCC should be objective of further investigations.

Keywords

mTOR Metastasis Everolimus Phosphyorylation Kidney Clear cell 

Notes

Acknowledgements

We thank Ms. Ursula Kühs for her excellent technical assistance during tissue-microarray performance. The study was supported by a grant from Novartis AG, Basel, Switzerland.

Author contributions

Protocol development: SK, SR, JB. Data collection and experiments: SR, DS, JH, VS. Data analysis and interpretation: SR, DS, JB, VS. Study supervision: AS, JB. Manuscript writing/ editing: SR, JB, SK, AS.

Compliance with ethical standards

Conflict of interest

JB: consultancies, honoraria or study participation from Bayer, BMS, Eisai, Eusa, Immatics, Ipsen, Novartis, Pfizer and Roche. AS: consultancies, honoraria or study participation from Bayer, BMS, Eisai, Immatics, Ipsen, Novartis, Pfizer and Roche.

Ethical standards

The study was approved by the institutional review board and conducted in accordance with the Helsinki and START protocol. We take responsibility to the integrity of the data and accuracy of the reported study. All authors have made a substantial contribution to the information or material submitted for publication and approved the final version.

References

  1. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23:5853–5857.  https://doi.org/10.1038/sj.onc.1207721 CrossRefGoogle Scholar
  2. Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280:25485–25490.  https://doi.org/10.1074/jbc.M501707200 CrossRefGoogle Scholar
  3. Choe G et al (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746Google Scholar
  4. Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (New York, NY) 273:239–242CrossRefGoogle Scholar
  5. Copp J, Manning G, Hunter T (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821–1827.  https://doi.org/10.1158/0008-5472.can-08-3014 CrossRefGoogle Scholar
  6. Darwish OM et al (2013) Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 81:581–586.  https://doi.org/10.1016/j.urology.2012.11.030 CrossRefGoogle Scholar
  7. Grgic T, Mis L, Hammond JM (2011) Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma. Ann Pharmacother 45:78–83.  https://doi.org/10.1345/aph.1M288 CrossRefGoogle Scholar
  8. Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C (2011) PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest 29:427–438.  https://doi.org/10.3109/07357907.2011.584782 CrossRefGoogle Scholar
  9. Hager M, Haufe H, Alinger B, Kolbitsch C (2012) pS6 Expression in normal renal parenchyma primary renal cell carcinomas their metastases. Pathol Oncol Res 18:277–283.  https://doi.org/10.1007/s12253-011-9439-y CrossRefGoogle Scholar
  10. Haghighat A, Mader S, Pause A, Sonenberg N (1995) Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E The. EMBO J 14:5701–5709CrossRefGoogle Scholar
  11. Hara K et al (1997) Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272:26457–26463CrossRefGoogle Scholar
  12. Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281.  https://doi.org/10.1056/NEJMoa066838 CrossRefGoogle Scholar
  13. Hudson CC et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014CrossRefGoogle Scholar
  14. Kononen J et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847CrossRefGoogle Scholar
  15. Kruck S et al (2010) Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncol Rep 23:159–163Google Scholar
  16. Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J (2014) Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer 14:376.  https://doi.org/10.1186/1471-2407-14-376 CrossRefGoogle Scholar
  17. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE (2006) Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36:283–293Google Scholar
  18. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA (2011) The epidemiology of renal cell carcinoma. Eur Urol 60:615–621.  https://doi.org/10.1016/j.eururo.2011.06.049 CrossRefGoogle Scholar
  19. Nishikawa M, Miyake H, Harada K, Fujisawa M (2014a) Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors Medical. Oncology 31:792  https://doi.org/10.1007/s12032-013-0792-4 Google Scholar
  20. Nishikawa M, Miyake H, Harada K, Fujisawa M (2014b) Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: effect on prognostic outcomes following radical nephrectomy. Urol Oncol 32:49e15–49e21.  https://doi.org/10.1016/j.urolonc.2013.07.014 CrossRefGoogle Scholar
  21. Oshiro N et al (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells Devoted Mol Cell Mech 9:359–366.  https://doi.org/10.1111/j.1356-9597.2004.00727.x CrossRefGoogle Scholar
  22. Pantuck AJ et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267.  https://doi.org/10.1002/cncr.22677 CrossRefGoogle Scholar
  23. Rosenwald IB et al (1995) Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 270:21176–21180CrossRefGoogle Scholar
  24. Schultz L et al (2011) Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 35:1549–1556.  https://doi.org/10.1097/PAS.0b013e31822895e5 CrossRefGoogle Scholar
  25. Turajlic S, Swanton C (2016) Metastasis as an evolutionary process. Science 352:169–175.  https://doi.org/10.1126/science.aaf2784 CrossRefGoogle Scholar
  26. Voss MH et al (2014) Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clin Cancer Res 20:1955–1964.  https://doi.org/10.1158/1078-0432.CCR-13-2345 CrossRefGoogle Scholar
  27. Wittekind LHS Ce (2002) International union against cancer (UICC): TNM classification of malignant tumors, 6th edn. edn. Wiley-Liss, New YorkGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Steffen Rausch
    • 1
  • Daniel Schollenberger
    • 1
  • Joerg Hennenlotter
    • 1
  • Viktoria Stühler
    • 1
  • Stephan Kruck
    • 1
  • Arnulf Stenzl
    • 1
  • Jens Bedke
    • 1
    Email author
  1. 1.Department of UrologyUniversity Hospital TübingenTübingenGermany

Personalised recommendations